Prix Galien Awards
Moderna’s updated COVID-19 mRNA vaccine approved by MHRA
The updated vaccine will be available to eligible groups as part of the 2026/27 NHS vaccination programme
Pfizer and BioNTech’s XFG-adapted COVID-19 vaccine approved by US FDA
The 2026-2027 vaccine targets the XFG variant to more closely match current variants
MSD and Moderna announce potential new vaccine for melanoma
The mRNA-based therapy, used with Keytruda, is designed specifically for each patient
Moderna appoints Piyali Mukherjee as Head of Medical Affairs, Europe and Middle East
Mukherjee has previously held senior leadership roles at Moderna and GSK
Moderna and Merck announce data from melanoma combination therapy study
Skin cancer is one of the most common cancers in the US, with melanoma accounting for the majority of skin cancer deaths
Invivyd working with FDA towards potential Biologics License Application for COVID-19
The company plans head-to-head safety evaluation with COVID-19 vaccine, pending regulatory alignment
FDA approves Pfizer and BioNTech’s jab for COVID-19
Globally, five billion doses of the companies’ vaccine have been distributed
Moderna’s LP.8.1-adapted COVID-19 vaccine recommended by CHMP
Global health authorities have recommended that vaccines for the 2025-2026 season should target LP.8.1
Moderna shares positive phase 3 results for mRNA flu vaccine candidate
More than 600,000 people in the US were hospitalised due to flu-related illness last year
Moderna’s RSV vaccine mRESVIA granted FDA approval to protect younger adults
The vaccine is already approved in the US for use in adults aged 60 years and older
Moderna’s RSV vaccine mRESVIA granted MHRA approval to protect older adults
RSV is responsible for 14,000 hospitalisations per year in UK adults aged 65 years and older
EC approves CSL/Arcturus’ self-amplifying mRNA COVID-19 vaccine Kostaive
Kostaive is designed to instruct the body to make more mRNA to boost immune response